Physician profile
Thomas Beamer
NPI 1538273933
$2,586.41
in general payments reported to CMS, 2019-2025
21 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $1,098 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $555.26 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $475.13 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $238.59 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $187.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.71 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $153.53 | 2019-2020 | |
| Pfizer INC. | $152.32 | 2019-2020 | |
| Amarin Pharma, INC. | $115.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $101.90 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $82.85 | 2019-2020 | |
| Allergan, INC. | $66.74 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $53.43 | 2019 | |
| Glaxosmithkline, LLC. | $43.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.38 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.85 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $23.87 | 2019 | |
| Exact Sciences Corporation | $21.35 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $20.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.08 | 2025 | |
| Therapeuticsmd, INC. | $15.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Beamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.